LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis
NCT ID: NCT05186116
Last Updated: 2025-09-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
25 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-01-01
Study Completion Date
2032-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT, partial or whole graft LT from deceased donors for unresectable CRLM.
Secondary outcomes are graft survival and donor outcomes in terms of safety and quality of life.
Donor selection is performed according to the currently used Institutional and National standards and protocols.
Secondary outcomes are graft survival and donor outcomes in terms of safety and quality of life.
Donor selection is performed according to the currently used Institutional and National standards and protocols.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
NCT05185245
Liver Metastasis Colon Cancer
Colorectal Cancer
RECRUITING
NA
A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program
NCT02218801
Liver Metastasis
Colorectal Carcinoma
COMPLETED
Living Donor Liver Transplantation for CRC Liver Metastases
NCT05175092
Liver Metastasis Colon Cancer
WITHDRAWN
NA
Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases
NCT03488953
Colorectal Cancer Metastatic
Liver Metastases
RECRUITING
NA
Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
NCT04616495
Colorectal Cancer
Metastatic Liver Cancer
Liver Metastases
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Liver Transplant (LT) is a feasible, safe and effective curative strategy for patients with unresectable colorectal liver metastases (CRLM), and several trials are currently active and in a recruitment phase to study its impact with both conventional donors and living donors (LDLT).
As a matter of fact, in this setting living donors represent a helpful resource, thanks to the opportunity to schedule the LT at the timeliest conditions in terms of oncological response and patient's performance status. LDLT is a well-established procedure that is already offered to patients listed for LT at our Institution.
Crucial requirement for study eligibility is the assessment of non-resectability of the presented liver metastases from colorectal cancer (CRC).
Criteria for non-resectability of the liver-only CRC metastases eligible for the study should be assessed at the patient study entry, by the surgeon in charge together with the multidisciplinary team.
Patients fulfilling the inclusion criteria of the study will undergo clinical, translational and regulatory steps. Briefly, the main procedures and requirements of the study can be summarized as follows:
\- Pre-transplant screening and waiting phase:
Screening of patients with liver-limited CRC metastases potentially eligible to the study will be registered. The screening for general eligibility to liver transplantation will be conducted according to the existing Institutional protocol (called in Italian "PDTA", "Percorso Diagnostico Terapeutico Assistenziale").
During screening or waiting time periods, patients will continue planned chemotherapy treatment and will undergo blood tests (including CEA and Ca19.9), thoraco-abdominal CT scan and positron emission tomography (PET) scan (if needed) every 8 weeks.
\- Donors' screening:
Screening of donors will be held according to the existing Institutional protocol for LDLT
\- Informed consent:
Consent to the study will be signed after completion of the pre-LT screening, that is once co-morbidities and transplant eligibility will be ascertained on top of cancer conditions. In addition, patients will have to sign additional written informed consent prior to any study procedure.
\- Post-transplant follow-up:
Following LDLT, standard institutional follow-up procedures will be performed and registered. Patient/graft condition and tumor status should be re-assessed at least every 4 months for the first 3 years, every 6 months for the rest of follow-up.
Following donation standard institutional follow up will be performed on donors and registered.
As a matter of fact, in this setting living donors represent a helpful resource, thanks to the opportunity to schedule the LT at the timeliest conditions in terms of oncological response and patient's performance status. LDLT is a well-established procedure that is already offered to patients listed for LT at our Institution.
Crucial requirement for study eligibility is the assessment of non-resectability of the presented liver metastases from colorectal cancer (CRC).
Criteria for non-resectability of the liver-only CRC metastases eligible for the study should be assessed at the patient study entry, by the surgeon in charge together with the multidisciplinary team.
Patients fulfilling the inclusion criteria of the study will undergo clinical, translational and regulatory steps. Briefly, the main procedures and requirements of the study can be summarized as follows:
\- Pre-transplant screening and waiting phase:
Screening of patients with liver-limited CRC metastases potentially eligible to the study will be registered. The screening for general eligibility to liver transplantation will be conducted according to the existing Institutional protocol (called in Italian "PDTA", "Percorso Diagnostico Terapeutico Assistenziale").
During screening or waiting time periods, patients will continue planned chemotherapy treatment and will undergo blood tests (including CEA and Ca19.9), thoraco-abdominal CT scan and positron emission tomography (PET) scan (if needed) every 8 weeks.
\- Donors' screening:
Screening of donors will be held according to the existing Institutional protocol for LDLT
\- Informed consent:
Consent to the study will be signed after completion of the pre-LT screening, that is once co-morbidities and transplant eligibility will be ascertained on top of cancer conditions. In addition, patients will have to sign additional written informed consent prior to any study procedure.
\- Post-transplant follow-up:
Following LDLT, standard institutional follow-up procedures will be performed and registered. Patient/graft condition and tumor status should be re-assessed at least every 4 months for the first 3 years, every 6 months for the rest of follow-up.
Following donation standard institutional follow up will be performed on donors and registered.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Colon Adenocarcinoma
Liver Metastasis Colon Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LDLT, partial graft, whole graft recipients
Patients that undergo LDLT, partial graft or whole graft transplantation for CRLM in the study period
Group Type
EXPERIMENTAL
Living donor liver transplant, Split liver transplant, RAPID, DDLT
Intervention Type
PROCEDURE
Transplantation of part of the liver from a living donor, or entire cadaveric graft
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Living donor liver transplant, Split liver transplant, RAPID, DDLT
Transplantation of part of the liver from a living donor, or entire cadaveric graft
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18.
* Histologically confirmed colon and rectum (intraperitoneal) adenocarcinoma.
* Pathological classification of primary tumor as pT1-3, without peritoneal tumor deposits, absence of mucinous component \>50%, confirmed R0 resection, no limitations for RAS mutations, B-RAF wild type.
* No signs of extra hepatic metastatic disease or local recurrence according to CT scan+MRI+PET/CT scans.
* Liver metastases not eligible for curative liver resection
* Objective response according to RECIST 1.1 to first-line treatment, with sustained response for at least 4 months, OR disease control (complete \[CR\] or partial response \[PR\] or standard disease \[SD\]) during second- line treatment for at least 4 months.
* Carcinoembryonic Antigen (CEA) values stable or decreasing during the enrollment prior to liver transplant.
* Performance status, ECOG (Eastern Cooperative Oncology Group) 0-2.
* Signed informed consent and expected cooperation of the patients for the treatment and follow-up, and national/local regulations.
* Histologically confirmed colon and rectum (intraperitoneal) adenocarcinoma.
* Pathological classification of primary tumor as pT1-3, without peritoneal tumor deposits, absence of mucinous component \>50%, confirmed R0 resection, no limitations for RAS mutations, B-RAF wild type.
* No signs of extra hepatic metastatic disease or local recurrence according to CT scan+MRI+PET/CT scans.
* Liver metastases not eligible for curative liver resection
* Objective response according to RECIST 1.1 to first-line treatment, with sustained response for at least 4 months, OR disease control (complete \[CR\] or partial response \[PR\] or standard disease \[SD\]) during second- line treatment for at least 4 months.
* Carcinoembryonic Antigen (CEA) values stable or decreasing during the enrollment prior to liver transplant.
* Performance status, ECOG (Eastern Cooperative Oncology Group) 0-2.
* Signed informed consent and expected cooperation of the patients for the treatment and follow-up, and national/local regulations.
Exclusion Criteria
* Hereditary CRC syndromes including FAP (Familial adenomatous polyposis) and Lynch syndrome.
* Prior extra hepatic metastatic disease or primary tumor local relapse.
* Palliative resection of primary CRC tumor.
* Disease progression
* Other malignancies in the previous 5 years (with exception of in situ cervical carcinoma and basal cell carcinoma; superficial bladder tumors are allowed if curatively treated).
* Active intra-venous or alcohol abusers (patients may be eligible if abstention \> 6 months is demonstrated)
* Active HIV infection
* Psychiatric disorders and patient low compliance
* Any reason why, in the judgment of the investigators, the patient should not participate (to be formally declared)
* Prior extra hepatic metastatic disease or primary tumor local relapse.
* Palliative resection of primary CRC tumor.
* Disease progression
* Other malignancies in the previous 5 years (with exception of in situ cervical carcinoma and basal cell carcinoma; superficial bladder tumors are allowed if curatively treated).
* Active intra-venous or alcohol abusers (patients may be eligible if abstention \> 6 months is demonstrated)
* Active HIV infection
* Psychiatric disorders and patient low compliance
* Any reason why, in the judgment of the investigators, the patient should not participate (to be formally declared)
Minimum Eligible Age
18 Years
Maximum Eligible Age
77 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Ospedaliero-Universitaria di Modena
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fabrizio Di Benedetto
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliero Universitaria di Modena
Modena, MO, Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155.
Reference Type
BACKGROUND
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21. doi: 10.1097/00000658-199909000-00004.
Reference Type
BACKGROUND
Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg. 2001 Feb;88(2):165-75. doi: 10.1046/j.1365-2168.2001.01658.x.
Reference Type
BACKGROUND
Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.
Reference Type
BACKGROUND
Lang H, de Santibanes E, Schlitt HJ, Malago M, van Gulik T, Machado MA, Jovine E, Heinrich S, Ettorre GM, Chan A, Hernandez-Alejandro R, Robles Campos R, Sandstrom P, Linecker M, Clavien PA. 10th Anniversary of ALPPS-Lessons Learned and quo Vadis. Ann Surg. 2019 Jan;269(1):114-119. doi: 10.1097/SLA.0000000000002797.
Reference Type
BACKGROUND
Wicherts DA, de Haas RJ, Salloum C, Andreani P, Pascal G, Sotirov D, Adam R, Castaing D, Azoulay D. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg. 2013 May;100(6):808-18. doi: 10.1002/bjs.9088. Epub 2013 Mar 12.
Reference Type
BACKGROUND
Butte JM, Gonen M, Allen PJ, Peter Kingham T, Sofocleous CT, DeMatteo RP, Fong Y, Kemeny NE, Jarnagin WR, D'Angelica MI. Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. Ann Surg Oncol. 2015 Aug;22(8):2761-71. doi: 10.1245/s10434-015-4370-1. Epub 2015 Jan 9.
Reference Type
BACKGROUND
Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA, Poston G. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283-301. doi: 10.2147/CLEP.S34285. Epub 2012 Nov 7.
Reference Type
BACKGROUND
Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008 Jan;13(1):51-64. doi: 10.1634/theoncologist.2007-0142.
Reference Type
BACKGROUND
Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, Lee PH. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007 Feb;14(2):786-94. doi: 10.1245/s10434-006-9215-5. Epub 2006 Nov 14.
Reference Type
BACKGROUND
Hill CR, Chagpar RB, Callender GG, Brown RE, Gilbert JE, Martin RC 2nd, McMasters KM, Scoggins CR. recurrence following hepatectomy for metastatic colorectal cancer: development of a model that predicts patterns of recurrence and survival. Ann Surg Oncol. 2012 Jan;19(1):139-44. doi: 10.1245/s10434-011-1921-y. Epub 2011 Jul 13.
Reference Type
BACKGROUND
Muhlbacher F, Huk I, Steininger R, Gnant M, Gotzinger P, Wamser P, Banhegyi C, Piza F. Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? Transplant Proc. 1991 Feb;23(1 Pt 2):1567-8. No abstract available.
Reference Type
BACKGROUND
Toso C, Pinto Marques H, Andres A, Castro Sousa F, Adam R, Kalil A, Clavien PA, Furtado E, Barroso E, Bismuth H; Compagnons Hepato-Biliaires Group. Liver transplantation for colorectal liver metastasis: Survival without recurrence can be achieved. Liver Transpl. 2017 Aug;23(8):1073-1076. doi: 10.1002/lt.24791. No abstract available.
Reference Type
BACKGROUND
Grut H, Dueland S, Line PD, Revheim ME. The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):218-225. doi: 10.1007/s00259-017-3843-9. Epub 2017 Oct 12.
Reference Type
BACKGROUND
D'Angelica M, Kornprat P, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol. 2011 Apr;18(4):1096-103. doi: 10.1245/s10434-010-1409-1. Epub 2010 Nov 2.
Reference Type
BACKGROUND
Moris D, Tsilimigras DI, Chakedis J, Beal EW, Felekouras E, Vernadakis S, Schizas D, Fung JJ, Pawlik TM. Liver transplantation for unresectable colorectal liver metastases: A systematic review. J Surg Oncol. 2017 Sep;116(3):288-297. doi: 10.1002/jso.24671. Epub 2017 May 17.
Reference Type
BACKGROUND
Hagness M, Foss A, Egge TS, Dueland S. Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2014 Apr;21(4):1323-9. doi: 10.1245/s10434-013-3449-9. Epub 2013 Dec 27.
Reference Type
BACKGROUND
Dueland S, Syversveen T, Solheim JM, Solberg S, Grut H, Bjornbeth BA, Hagness M, Line PD. Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. Ann Surg. 2020 Feb;271(2):212-218. doi: 10.1097/SLA.0000000000003404.
Reference Type
BACKGROUND
Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, Line PD, Dueland S. Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. Br J Surg. 2018 Feb;105(3):295-301. doi: 10.1002/bjs.10651. Epub 2017 Nov 23.
Reference Type
BACKGROUND
Line PD, Hagness M, Berstad AE, Foss A, Dueland S. A Novel Concept for Partial Liver Transplantation in Nonresectable Colorectal Liver Metastases: The RAPID Concept. Ann Surg. 2015 Jul;262(1):e5-9. doi: 10.1097/SLA.0000000000001165.
Reference Type
BACKGROUND
Konigsrainer A, Templin S, Capobianco I, Konigsrainer I, Bitzer M, Zender L, Sipos B, Kanz L, Wagner S, Nadalin S. Paradigm Shift in the Management of Irresectable Colorectal Liver Metastases: Living Donor Auxiliary Partial Orthotopic Liver Transplantation in Combination With Two-stage Hepatectomy (LD-RAPID). Ann Surg. 2019 Aug;270(2):327-332. doi: 10.1097/SLA.0000000000002861.
Reference Type
BACKGROUND
Grat M, Krawczyk M, Stypulkowski J, Morawski M, Krasnodebski M, Wasilewicz M, Lewandowski Z, Grat K, Patkowski W, Zieniewicz K. Prognostic Relevance of a Complete Pathologic Response in Liver Transplantation for Hepatocellular Carcinoma. Ann Surg Oncol. 2019 Dec;26(13):4556-4565. doi: 10.1245/s10434-019-07811-z. Epub 2019 Sep 13.
Reference Type
BACKGROUND
Dueland S, Foss A, Solheim JM, Hagness M, Line PD. Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma. Br J Surg. 2018 May;105(6):736-742. doi: 10.1002/bjs.10769. Epub 2018 Mar 13.
Reference Type
BACKGROUND
Dueland S, Grut H, Syversveen T, Hagness M, Line PD. Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis. Am J Transplant. 2020 Feb;20(2):530-537. doi: 10.1111/ajt.15682. Epub 2019 Nov 28.
Reference Type
BACKGROUND
Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014 Oct;25(10):1995-2001. doi: 10.1093/annonc/mdu275. Epub 2014 Jul 23. Erratum In: Ann Oncol. 2015 Feb;26(2):445. doi: 10.1093/annonc/mdu548.
Reference Type
BACKGROUND
Brudvik KW, Vauthey JN. Surgery: KRAS mutations and hepatic recurrence after treatment of colorectal liver metastases. Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):638-639. doi: 10.1038/nrgastro.2017.129. Epub 2017 Sep 20. No abstract available.
Reference Type
BACKGROUND
Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. doi: 10.1158/1078-0432.CCR-18-4070. Epub 2019 Feb 20.
Reference Type
BACKGROUND
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20.
Reference Type
BACKGROUND
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693-9. doi: 10.1056/NEJM199603143341104.
Reference Type
BACKGROUND
Line PD, Ruffolo LI, Toso C, Dueland S, Nadalin S, Hernandez-Alejandro R. Liver transplantation for colorectal liver metastases: What do we need to know? Int J Surg. 2020 Oct;82S:87-92. doi: 10.1016/j.ijsu.2020.03.079. Epub 2020 Apr 17.
Reference Type
BACKGROUND
Sinha PK, Mohapatra N, Bharathy KG, Kumar G, Pamecha V. A Long-Term Prospective Study of Quality of Life, Abdominal Symptoms, and Cosmesis of Donors After Hepatectomy for Live-Donor Liver Transplantation. J Clin Exp Hepatol. 2021 Sep-Oct;11(5):579-585. doi: 10.1016/j.jceh.2020.11.005. Epub 2020 Dec 7.
Reference Type
BACKGROUND
Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD, Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC, Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):933-946. doi: 10.1016/S2468-1253(21)00219-3. Epub 2021 Sep 8.
Reference Type
BACKGROUND
Ladner DP, Dew MA, Forney S, Gillespie BW, Brown RS Jr, Merion RM, Freise CE, Hayashi PH, Hong JC, Ashworth A, Berg CL, Burton JR Jr, Shaked A, Butt Z. Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). J Hepatol. 2015 Feb;62(2):346-53. doi: 10.1016/j.jhep.2014.08.043. Epub 2014 Sep 6.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
470/2021/SPER/AOUMO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
NCT05248581
RECRUITING
Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases
NCT02864485
RECRUITING
NA
Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection
NCT06698146
RECRUITING
Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy
NCT02597348
ACTIVE_NOT_RECRUITING
NA
Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.
NCT02331641
COMPLETED
Liver Transplantation and Metastatic Colo-rectal Cancer.
NCT00294827
ACTIVE_NOT_RECRUITING
PHASE2
The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases
NCT04161092
ACTIVE_NOT_RECRUITING
NA
Colorectal Liver Metastases: Novel Assessment Tools for Technical Resectability
NCT04270851
UNKNOWN
LT for Unresectable Colorectal Liver Metastasis
NCT04874259
RECRUITING
NA
Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research
NCT05398380
RECRUITING
NA
Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways
NCT02456285
COMPLETED
Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors
NCT04870879
RECRUITING
NA
Chemotherapy for Resectable Colorectal Liver Metastases
NCT04513457
COMPLETED
The Inflammatory Response to Stress and Angiogenesis in Liver Resection
NCT03131778
COMPLETED
NA
Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis
NCT01565811
COMPLETED
Long-term Outcomes After Breast Cancer Liver Metastasis Surgery: an European, Retrospective, Snapshot Study
NCT04817813
UNKNOWN
Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)
NCT05265169
RECRUITING
NA
NON-COlorectal Liver METastases Undergoing Liver Resection
NCT06542926
NOT_YET_RECRUITING
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
NCT05195710
RECRUITING
PHASE1
Open vs Laparoscopic Liver Surgery for Colorectal Liver Metastases
NCT02727179
COMPLETED
NA
International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE
NCT07191548
NOT_YET_RECRUITING
NA
Perioperative Outcomes of Simultaneous Colorectal and Liver Resections
NCT05475041
COMPLETED
National Registry of Hepatic Metastases From Non-Colorectal Cancer"
NCT07180641
COMPLETED